Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380(15):1450–1462

Article  CAS  PubMed  Google Scholar 

Loomba R, Lim JK, Patton H et al (2020) AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 158(6):1822–1830

Article  PubMed  Google Scholar 

Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6

Article  PubMed  Google Scholar 

Pang RW, Poon RT (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl 1):30–44

Article  CAS  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905

Article  CAS  PubMed  Google Scholar 

Yau T, Park JW, Finn RS et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23(1):77–90

Article  CAS  PubMed  Google Scholar 

Verset G, Borbath I, Karwal M et al (2022) Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin Cancer Res 28(12):2547–2554

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8). https://doi.org/10.1056/EVIDoa2100070

Park R, Lopes da Silva L, Nissaisorakarn V et al (2021) Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. J Hepatocell Carcinoma 8:145–54

Article  PubMed  PubMed Central  Google Scholar 

Fong KY, Zhao JJ, Sultana R et al (2023) First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis. Liver Cancer 12(1):7–18

Article  PubMed  Google Scholar 

Sonbol MB, Riaz IB, Naqvi SAA et al (2020) Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol 6(12):e204930

Article  PubMed  PubMed Central  Google Scholar 

Mould DR (2012) Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther 92(3):283–286

Article  CAS  PubMed  Google Scholar 

Upreti VV, Venkatakrishnan K (2019) Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence. Clin Pharmacol Ther 106(5):981–992

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898

Article  PubMed  Google Scholar 

Schünemann HJ, Cuello C, Akl EA et al (2019) GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 111:105–114

Article  PubMed  Google Scholar 

Fukumura D, Kloepper J, Amoozgar Z et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325–340

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn E, Araki K, Hashimoto M et al (2018) Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A 115(18):4749–4754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huinen ZR, Huijbers EJM, van Beijnum JR et al (2021) Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 18(8):527–540

Article  PubMed  Google Scholar 

Rao Q, Li M, Xu W et al (2020) Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 14(5):765–775

Article  PubMed  Google Scholar 

Xu H, Cao D, Zheng Y et al (2021) Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol 100:108135

Article  CAS  PubMed  Google Scholar 

Zheng J, Shao M, Yang W et al (2022) Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol 112:109244

Article  CAS  PubMed  Google Scholar 

Jiang Y, Chen M, Nie H et al (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15(5):1111–1122

Article  PubMed  PubMed Central  Google Scholar 

Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175(11):7746–7754

Article  CAS  PubMed  Google Scholar 

Kudo M (2019) Scientific rationale for combination immunotherapy of hepatocellular carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 antibodies. Liver Cancer 8(6):413–426

Article  PubMed  PubMed Central  Google Scholar 

Zierhut ML, Chen Y, Pithavala YK et al (2016) Clinical trial simulations from a model-based meta-analysis of studies in patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. CPT Pharmacometrics Syst Pharmacol 5(5):274–282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruix J, Chan SL, Galle PR et al (2021) Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 75(4):960–974

Article  CAS  PubMed  Google Scholar 

Boucher M, Bennetts M (2018) Many flavors of model-based meta-analysis: part II - modeling summary level longitudinal responses. CPT Pharmacometrics Syst Pharmacol 7(5):288–297

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151–172

Article  CAS  PubMed  Google Scholar 

Kolamunnage-Dona R, Berhane S, Potts H et al (2021) Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 75(4):879–887

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cabibbo G, Cucchetti A, Cammà C et al (2019) Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol 15(29):3411–3422

Article  CAS  PubMed